anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1308483 Dentifrice and mouthwash composition BLENDAX-WERKE R SCHNEIDER & CO 5 Nov 1970 [7 Nov 1969] 52688/70 Heading A5B A composition for care of the mouth comprises a fluorine compound and rutin or pantothenic acid or a derivative thereof. The composition may also include vitamin K 3  in the form of its sodium bisulphite compound, a water-soluble phosphate, a preservative, a tooth-polishing agent, a scent, a flavouring substance, a surface active agent, a thickening agent, a moistening agent, a dye and/or an enzyme. The composition may be in the form of a toothpaste, gel, tablet, mouthwash or chewing gum. In Examples, the following ingredients are specified: fluorine compoundssodium monofluorophosphate, sodium fluoride. sodium hexafluorophosphate and ethanolamine hydrofluoride, rutin in the form of its sodium sulphate ester, pantothenic acid derivative-panthenol,water-soluble phosphates-sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, disodium glycerophosphate, dicalcium phosphate dihydrate, and fructose-1, 6-diphosphate, preservatives-hexachlorophene, bromochlorophene and methyl, ethyl and propyl p-hydroxybenzoates, tooth-polishing agents-silica, polyamide powder, calcium pyrophosphate and potassium metaphosphate, surface active agents-sodium N- lauryl sarcoside, sodium lauryl sulphate, lauryl diethylamine oxide and cetyl pyrimidine chloride, thickening agents-carboxymethyl cellulose, silica gel, hydroxypropyl cellulose, sodium alginate, polyethylene glycol and polymethyl methacrylate, moistening agents-glycerol, and sorbitol and enzyme-protease. The compositions may be dispersed in water, aqueous ethanol or aqueous sodium hydroxide.
PURPOSE:To provide a base sequence giving an antibody to human acute leukemia lymphoma, and composed of a specific nucleic acid base sequence and a polynucleotide having a base sequence complementary to the above base sequence. CONSTITUTION:The cell of mouse hybridoma NL-1 is treated with a protease to extract the DNA, which is centrifuged and dialyzed to obtain a mouse chro mosome DNA (A). The component A is digested completely with restriction endonuclease EcoRI, and subjected to agarose electrophoresis to effect the extraction of the DNA fragment (B). The fragment B is linked with Shallon 4A vector EcoRIarm using T4DNA ligase to obtain a mouse NL-1 gene library (C). The component C is selected by plaque hybridization to separate the gene (D) containing the whole V-region of the mouse NL-1. The plasmid (PBR NL-I-H) obtained from the component D is incised with a restriction nuclease, and the base sequence of formula is determined from the incision fragment.
In an effort to reduce heavy drinking, participants will be asked to complete a daily monitoring assessment each morning for 14 days. Based on their responses, they will be provided a coping skill to either directly address their alcohol use or attempt to improve their emotion regulation and distress tolerance skills.
In each of the 3 cohorts, 6 subjects were planned to be randomised to receive KAND567. The dose levels were 33.8 mg/6 h (cohort 1), 67 mg/6 h (cohort 2), or 134 mg/6 h (cohort 3).
PURPOSE OF REVIEW: This review summarizes current literature about the relationships between macro and microcirculation and their practical clinical implications in children with septic shock.
RECENT FINDINGS: Current evidence from experimental and clinical observational studies in children and adults with septic shock reveals that the response to treatment and resuscitation is widely variable. Furthermore, there is a loss of hemodynamic coherence, as resuscitation-induced improvement in macrocirculation (systemic hemodynamic parameters) does not necessarily result in a parallel improvement in the microcirculation. Therefore, patient-tailored monitoring is essential in order to adjust treatment requirements during resuscitation in septic shock. Optimal monitoring must integrate macrocirculation (heart rate, blood pressure, cardiac output, and ultrasound images), microcirculation (videomicroscopy parameters and capillary refill time) and cellular metabolism (lactic acid, central venous blood oxygen saturation, and difference of central venous to arterial carbon dioxide partial pressure).
SUMMARY: There is a dire need for high-quality studies to assess the relationships between macrocirculation, microcirculation and tissue metabolism in children with septic shock. The development of reliable and readily available microcirculation and tissue perfusion biomarkers (other than lactic acid) is also necessary to improve monitoring and treatment adjustment in such patients.
Cystic fibrosis (CF) related diabetes (CFRD) and glucose intolerance affects more than 50%-75% of teens and adults with CF. The 1998 North American CF Foundation on CFRD categorized the disease differently than other types of diabetes: CFRD with fasting hyperglycemia (FH), CFRD without FH and transient CFRD. The outcome of this consensus conference was the use of insulin as the only recommended treatment of CFRD. Although the conference report mandated treatment for CFRD with FH, treatment was not mandated for the other types of CFRD, the choice to treat was left to the clinician's discretion. However, insulin was the only recommended therapy for all types of CFRD. Although some clinicians have used basal bolus regimens as the insulin management, many still use NPH. Given the need for CF patients to eat many frequent meals and snacks to maintain their weight, use of NPH insulin rarely renders good glycemic control. A basal bolus regimen is much more physiologic and would allow good glycemic control even with frequent meals and snacks. To date, there are no studies documenting safety and efficacy of true basal insulin, or a basal bolus regimen. Furthermore, protein catabolism and excessive muscle loss has been well documented in CF patients, both in those with and those without, glucose intolerance. Studies by our group and others have documented that a major reason for the catabolism is resistance to insulin's anti-catabolic effects on protein turnover. Thus, there is potential clinical benefit of improving muscle mass and general health by insulin treatment even for CF patients who do not have fasting hyperglycemia. A non-peaking basal insulin would be the only reasonable choice, yet studies are lacking. Our overall goal is to study the safety and efficacy of LevemirTM for the improvement of glycemic control of patients with CFRD. As a second goal, we will explore the ability of this basal insulin to improve protein catabolism and muscle mass. The study will be conducted as a six month trial.
Depression is a major public health problem worldwide and is closely related with systemic inflammatory responses. Additionly, physical activity (PA) is thought to be associated with lower levels of depression and inflammatory markers. This study aimed to elucidate the complex interactions between PA, depression, and inflammatory markers. Based on the National Health and Nutrition Examination Survey (NHANES), various logistic regression were applied to analyze the pairwise correlations among the three. Restrictive cubic splines were constructed to explore the nonlinear relationship between PA and depression. Mediation models were used to identify the mediating role of inflammatory markers. The findings revealed a positive link between depression and inflammatory marker, whereas PA was inversely correlated with both inflammatory marker and depression. Particularly, we noticed the greatest reduction in the risk of depression when the level of PA was between 1200 and 1722 MET-min/week. Besides, we demonstrated that inflammatory markers mediate the potential effects of physical inactivity on depression, ranging from 1.72 % to 6.25 %. In conclusion, PA appear to protect against depression, in which inflammatory markers may play a mediating role. Moreover, we determined the optimal dosage of PA to minimize the likelihood of depression, thereby offering valuable guidance for managing depression.
NEW MATERIAL:The 5-fluorouracil derivative of formula (R is acyl group derived from a trienoic higher fatty acid). EXAMPLE:1-(9,12,15-Octadecatrienoyl)-5-fluorouracil (1-alpha-linolenyl-5-fluorouracil). USE:Useful as a blood platelet coagulation inhibiting agent, especially as a preventive for the metastasis of cancer or a carcinostatic agent. Dose: about 100- 500mg of the active component daily for adult. Although the agent is preferably administered orally, intravenous injection is also permissible. PROCESS:The compound of formula can be prepared either by reacting a trienoic higher fatty acid with 5-fluorouracil in the presence of a condensation agent (preferably 2-chloro-1-methylpyridinium p-toluene-sulfonic acid salt, etc.), or by reacting 5-fluorouracil with a reactive derivative of a trienoic higher fatty acid.
BACKGROUND: Exact quantification of volumetric changes of the extremities is difficult and often error-prone. The aim of this study was to establish a standardized method based on 3-dimensional (3D) scans. Furthermore, this study tests the method in terms of reproducibility and evaluates volume changes after surgical therapy in patients suffering from lymphedema on the lower extremity.
METHODS: 3D scans of the lower limb were performed with a mobile 3D scanner; "repeatability" and "interobserver reliability" of digital volumetry were tested. Furthermore, the method was applied on 31 patients suffering from chronic lymphedema.
RESULTS: Calculations of repeatability of the volume based on 20 3D scans of the same lower leg showed a mean volume of 2.488 ± 0.011 liters (range: 2.470-2.510). The mean volume of the different examiners did not differ significantly (F(2,18) = 1.579, P = 0.233). The paired t-test showed a significant mean volume decrease of 375 mL (95% confidence interval = 245/505 mL) between pretreatment and post-treatment (t (30) = 5.892, P < 0.001).
CONCLUSIONS: 3D volumetry is a noninvasive, easy, and quick method to assess volume changes of the lower leg. Other than the low costs, it is reproducible and precise and therefore ideal for evolution of therapy in lymphedema.
The existing body of research underscores the critical impact of intratumoral microbiomes on the progression of pancreatic ductal adenocarcinoma (PDAC), particularly in reshaping the tumor microenvironment and influencing gemcitabine resistance. However, peritumoral tissues' microbiome, distinct from PDAC tumors, remain understudied, and Western-centric analyses overlooking potential variations in dietary-influenced microbiomes. Our study addresses this gap by 16 S rRNA sequencing of PDAC tumors and matched peritumoral tissues from Chinese Mainland patients. Our research has uncovered that the microbiome composition within tumors and paired peritumoral tissues exhibits a high degree of similarity, albeit with certain discrepancies. Notably, Exiguobacterium is found to be more abundant within the tumor tissues. Further investigations have revealed that a lower Exiguobacterium/Bacillus ratio in both the tumor and peritumoral tissues of PDAC patients is indicative of a more favorable prognosis. Further exploration utilizing an orthotopic tumor model demonstrates that the probiotic Bacillus Coagulans impedes PDAC progression, accompanied by an increased infiltration of inflammatory neutrophils in tumors. Additionally, in the subgroup with a low Exiguobacterium/Bacillus ratio, whole-exome sequencing reveals elevated missense mutations in ABL2 and MSH2. The elevated expression of ABL2 and MSH2 has been correlated with poorer prognostic outcomes in PDAC patients. Together, these insights shed light on risk factors influencing PDAC progression and unveil potential therapeutic targets, alongside probiotic intervention strategies.
Patients receive talimogene laherparepvec IT on day 1. Cycles repeat every 3 weeks in cycle 1 and every 2 weeks thereafter in the absence of disease progression or unacceptable toxicity.
The timing of peritoneal dialysis (PD) initiation, whether conventional-start (planned) or urgent-start (unplanned), may impact the outcomes of PD and the rate of associated complications in individuals with chronic kidney disease (CKD). The goal of this study was to evaluate the effects of unplanned/urgent-start PD versus conventional-start PD in this cohort of patients. Electronic search of MEDLINE (via PubMed), EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and Scopus databases was done from inception until July 2023 for studies reporting outcomes of unplanned/urgent-start and conventional-start PD in CKD patients. Outcomes of interest included mechanical complications, post-procedure infections, mortality, and transfer to hemodialysis. Heterogeneity, publication bias, and the influence of individual studies on the pooled odds ratio (OR) with 95% confidence interval (CI) were evaluated. Twenty-seven studies were finally included in the review. The overall risk of post-procedure infectious was comparable for both PD initiation methods (OR: 1.05; 95% CI: 0.83-1.34). Similarly, the risks for peritonitis and exit site infections did not differ significantly. However, urgent-start PD correlated with a significantly higher risk of overall mechanical complications (OR: 1.70; 95% CI: 1.23-2.34). Specifically, the risk for leaks was notably higher (OR: 2.47; 95% CI: 1.67-3.65) in the urgent-start group compared to the conventional-start PD group. Urgent-start PD correlated with significantly increased mortality rates (OR: 1.83; 95% CI: 1.39-2.41). There was no difference in the likelihood of technique survival and transfer to hemodialysis. Both urgent-start and conventional-start PD correlated with similar risks of overall infectious complications. Urgent-start PD resulted in significantly increased risks of mechanical complications and mortality. Our findings emphasize the need for meticulous planning and consideration when opting for PD initiation.
The present invention comprises ligands and methods of manufacture thereof as well as pharmaceutical preparations including the ligands. The ligands may be human or humanized monoclonal antibodies and fragments, derivatives and homologs thereof. These may exhibit an unforeseen "plateau effect", i.e. the achievement of only a partial inactivation of a factor involved in hemostasis, in particular in the coagulation cascade, either individually or in combination even in molar excess. The ligands may bind to a factor or a complex of factors resulting in only partially impairing the function of a physiologically functional site of the said factor or factor complex even in molar excess. This makes the ligands particularly suitable for treating coagulation disorders and resulting thrombotic pathologic conditions while minimizing the risk of bleeding. Particularly useful is a property of ligands in accordance with the present invention to allow some physiological function of the affected site even when the ligand is in molar excess. The ligands may be anti-factor VIII antibodies or antibodies against a factor VIII complex, in particular human or human hybrid monoclonal antibodies which bind to factor VIII or a factor VIII complex and at least partially inhibit the activity of factor VIII.
Yaz is also indicated for the treatment of symptoms of premenstrual dysphoric disorder (PMDD) in women who choose to use an oral contraceptive as their method of contraception. The effectiveness of Yaz for PMDD when used for more than three menstrual cycles has not been evaluated. 

The essential features of PMDD according to the Diagnostic and Statistical Manual-4th edition (DSM-IV) include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. In this disorder, these symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school, or with usual social activities and relationships with others. Diagnosis is made by healthcare providers according to DSM-IV criteria, with symptomatology assessed prospectively over at least two menstrual cycles. In making the diagnosis, care should be taken to rule out other cyclical mood disorders. 

Yaz has not been evaluated for the treatment of premenstrual syndrome (PMS).
Healthy young subjects will participate in a 16-days hot and cold acclimation program. During cold procedure, the participant will be immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 5-min, and during hot procedure, the participant will be immersed in 45° water bath in semi recumbent position up to the level of the manubrium for 5-min.
FIELD: medicine. ^ SUBSTANCE: inventions relate to medicine, namely to oncology, and deals with treatment of liver cancer. For this purpose 4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid or its physiologically acceptable salt in dose from 10 to 30 mg per day is introduced. Treatment is carried out in accordance with therapeutic regimen, in accordance to which continuous daily introduction for from 1 to 4 weeks is performed. After that period of medication withdrawal for from 1 to 3 weeks follows. ^ EFFECT: inventions ensure essential reduction of side effects, such as deep vein thrombosis, and in addition considerably improve therapeutic effect of TAC-101 in treatment of liver cancer. ^ 4 ex
A propionamide derivative represented by general formula (I) and a salt thereof, wherein R?1 and R2¿ represent each hydrogen, etc.; R?3 and R4¿ are combined together to represent optionally substituted C¿2?-C7 alkylene, etc.; R?5¿ represents hydrogen, etc.; and R6 represents -X-CO-O-R7, etc. These compounds inhibit a neutral endopeptidase activity, have an improved oral absorbability, and can potentiate the biological effects of an atrial natriuretic peptide which is a potent natriuretic, diuretic and hypotensive hormone. Therefore, they are useful for treating various diseases of the circulatory organs, including hypertension, cardiac insufficiency, angina pectoris, renal insufficiency, premenstrual syndrome, cyclic edema, Ménière disease, aldosteronism (primary and secondary), pulmonary edema, hypereninemia, ascites and hypercalciuria, and for treating glaucoma. They are useful also for treating gastrointestinal diseases, particularly diarrhea and irritable colon syndrome, and pains.
Obstructive sleep apnea (OSA) is a sleep disorder that has been associated with the incidence of other pathologies. Diagnosis is mainly based on the apnea-hypopnea index (AHI) obviating other repercussions such as intermittent hypoxemia, which has been found to be associated to cardiovascular complications. Blood-based samples and urine have been the most utilised biofluids in metabolomics studies related to OSA, while sweat could be an alternative due to its non-invasive and accessible sampling, its reduced complexity, and comparability with other biofluids. Therefore, this research aimed to evaluate metabolic overnight changes in sweat collected from patients with OSA classified according to the AHI and oxygen desaturation index (ODI), looking for potential cardiovascular repercussions. Pre- and post-sleeping sweat samples from all individuals (n = 61) were analysed by gas chromatography coupled to high-resolution mass spectrometry after appropriate sample preparation to detect as many metabolites as possible. Permanent significant alterations in the sweat were reported for pyruvate, serine, lactose, and hydroxybutyrate. The most relevant overnight metabolic alterations in sweat were reported for lactose, succinate, urea, and oxoproline, which presented significantly different effects on factors such as the AHI and ODI for OSA severity classification. Overall metabolic alterations mainly affected energy production-related processes, nitrogen metabolism, and oxidative stress. In conclusion, this research demonstrated the applicability of sweat for evaluation of OSA diagnosis and severity supported by the detected metabolic changes during sleep.
The invention discloses a method for predicting a focus area in a histopathological image, and relates to the problem that the focus area is difficult to detect in the histopathological image analysis and diagnosis technology. The structural appearance information of the cell nucleus and cytoplasm is an important embodiment of the phenotype information of the histopathological image, and provides basis for classification. The key point of extracting the characteristics of the histopathological image is dyeing separation. However, the histopathological image has a large number of negative patterns, complex patterns and textures, color changes and artifacts, so that no accurate yin-yang classification method exists at present. Aiming at the problem, a model is designed by combining the characteristics of a task, the tissue pathology image is dyed and initialized by utilizing color deconvolution, the trained model is migrated to a focus area prediction task, and the positive probability is aggregated to generate a thermodynamic diagram. Experiments show that the method can effectively detect the focus area. The method is mainly applied to the focus area prediction task of the cytopathology image.
1. A formulation with a controlled release or delayed release for oral administration which is enteric coated tablets or caplets comprising a reaction complex formed by the interaction of (1) a calcium polycarbophil component which is a water-swellable, but water insoluble, fibrous cross-linked carboxy-functional polymer, said polymer containing (a) a plurality of repeating units of which at least about 80% contain at least one carboxyl functionality, and (b) about 0.05 to about 1.5% cross-linking agent substantially free from polyalkenyl polyether, said percentages being based upon the weights of unpolymerised repeating unit and cross-linking agent, respectively, with (2) water, in the presence of a paroxetine or a pharmaceutically acceptable salt thereof as an active agent. 2. A method of treating and/or preventing the disorders by administering an effective and/or a prophylactic amount of a controlled release or delayed release formulation according to any preceding claim, to a sufferer in need thereof. 3. Use of a controlled release or delayed release formulation according to claim 1 in the manufacture of a medicament, for treating and/or preventing the disorders. 4. A process for the preparation of a formulation according to claim 1 which comprises combining the constituents thereof in the required proportions.
Elective spinal surgery for the correction of degenerative spinal pathology may involve significant intraoperative risks that can influence postoperative neurologic outcomes. Spinal cord monitoring had made it possible to track the spine and nerve root sensory and motor tracts. This has improved the ability to conduct minimally invasive surgery by allowing surgeons to operate without direct visualization of the neurologic elements.

Intraoperative neuromonitoring (IONM) of the spinal cord is primarily accomplished by both somatosensory evoked potentials (SSEP) and transcranial motor evoked potentials (tcMEPs). Due to a shortage in personnel trained to evaluate neuro-monitoring results, surgeon-driven systems have been established. An example of a surgeon driven monitoring system is NeuroVision®, which interacts with the surgeon during the operation by providing real-time visible and auditory tcMEP and compound muscle action potential (CMAP) waveforms. This stands in comparison to hospital based methods of IONM.